<p>股息股票因多种原因成为了很好的投资选择。在价格下跌时买入更是不错，当然，前提是它们有能力反弹。</p>
<p>寻找符合这一特征的公司的投资者应当强烈考虑 <strong>辉瑞</strong>（PFE 0.22%）和 <strong>默克</strong>（MRK 1.86%）。这两家市场领导者在过去 12 个月的表现落后于大盘，但对于那些关注长期投资的人来说，它们仍然看起来具有吸引力。以下是详细情况。</p>
<p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1MzQvcGh5c2ljaWFuLWdpdmluZy1tZWRpY2luZS10by1lbGRlcmx5LXBhdGllbnQuanBnJnc9NzAw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1MzQvcGh5c2ljaWFuLWdpdmluZy1tZWRpY2luZS10by1lbGRlcmx5LXBhdGllbnQuanBnJnc9NzAw"/></p>
<p>图片来源：Getty Images。</p>
<h2>1. 辉瑞</h2>
<p>在过去几年中，辉瑞面临着财务结果恶化和某些产品竞争加剧的问题。它还面临失去其他产品专利保护的前景；这些产品包括 Eliquis，一种抗凝药，是其畅销药物之一，以及 Xtandi，一种癌症治疗药物。这两种药物将在未来几年内在美国失去专利。</p>
<p>这些挑战导致了糟糕的股市表现。然而，抛售可能已经过度。在当前水平下，辉瑞的股票看起来具有吸引力。</p>
<p>公司能够反弹并在长期内继续提供强劲回报的一个原因是其丰富的产品管线，特别是在肿瘤学领域，这是行业中最大的治疗领域之一。辉瑞目前拥有五种重磅癌症药物，并计划到 2030 年将这一数字提高到八种。</p>
<p>辉瑞在其他领域也有令人兴奋的候选药物，近年来获得了几种新产品的批准。尽管这些产品尚未对其收入增长产生显著贡献，但随着它们获得标签扩展，最终应该会有所贡献。</p>
<p>该公司的呼吸道合胞病毒（RSV）疫苗 Abrysvo 在第二季度产生了 1.43 亿美元的销售额，这对于一款在 2023 年获得批准的产品来说并不算差。它最近还在欧洲获得了针对 18 至 59 岁成人的标签扩展（之前仅适用于 60 岁及以上人群）。辉瑞应该会在 Abrysvo 和其他新产品的推出上取得进展。</p>
<p>公司还在减少开支。这些举措可能部分导致辉瑞在第二季度的盈利超出预期。管理层计划在今年实现 45 亿美元的净成本节约，并在未来几年继续追求进一步的减少，这些努力应该有助于提高盈利能力。</p>
<p>辉瑞是一只稳健的股息股票。其前瞻性收益率目前超过 7%，公司在过去五年中增加了 19.5% 的分红。尽管股票可能需要一些时间才能恢复，但辉瑞可能是寻求收入的投资者的优秀长期投资。</p>
<h2>2. 默克</h2>
<p>默克面临几个问题，其中最重要的是其畅销药物癌症药物 Keytruda 的竞争加剧，以及该药物在 2028 年即将到来的专利悬崖。此外，公司的第二季度业绩也不强劲：收入同比下降 2%，至 158 亿美元，而调整后的每股收益下降 7%，至 2.13 美元。</p>
<p>然而，公司也有一些亮点。最显著的是，Winrevair——其最新推出的药物之一，去年获得批准——报告销售额为 3.36 亿美元。Winrevair 是一种用于肺动脉高压的新机制治疗药物，预计很快将成为重磅药物。</p>
<p>默克在动物健康领域的业务表现也很好，该领域是其领导者之一，第二季度该细分市场的销售额同比增长 11%，达到 16 亿美元。</p>
<p>与此同时，默克有一些令人兴奋的产品管线候选药物，应该能帮助其克服与 Keytruda 相关的挑战。其中之一是 Keytruda 的皮下给药版本，已经通过了三期研究，将有助于延长该药物的专利保护。近年来，默克通过许可协议显著改善了其产品管线。其候选药物包括有前景的癌症产品和减肥药物。</p>
<p>正如 Winrevair 似乎是一个重大成功，默克也可能开发出创新疗法，以减轻潜在的 Keytruda 相关收入损失。因此，尽管最近遭遇挫折，但考虑到默克的创新历史，该业务可能会反弹。</p>
<p>谈到默克的股息计划，该公司目前提供 4.1% 的前瞻性收益率，过去五年中其股息增长了 39%。该股票仍然是股息投资者的良好选择。</p>

辉瑞

默克

<p>投资者被鼓励考虑辉瑞和默克作为在市场回调时值得购买的顶级分红股票。尽管辉瑞面临专利到期和竞争等挑战，但其在肿瘤学领域拥有强大的产品线，预期收益率超过 7%。默克虽然在其药物 Keytruda 面临竞争，但也有前景良好的新产品，预期收益率为 4.1%。过去五年中，这两家公司都大幅提高了分红，使其成为寻求收入的投资者的吸引选项</p>

<p>Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back.</p>
<div class="lb-trans"><p>股息股票因多种原因成为了很好的投资选择。在价格下跌时买入更是不错，当然，前提是它们有能力反弹。</p>
</div><p>Investors looking for companies that fit this profile should strongly consider <strong>Pfizer</strong>(PFE 0.22%) and <strong>Merck</strong>(MRK 1.86%). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown.</p>
<div class="lb-trans"><p>寻找符合这一特征的公司的投资者应当强烈考虑 <strong>辉瑞</strong>（PFE 0.22%）和 <strong>默克</strong>（MRK 1.86%）。这两家市场领导者在过去 12 个月的表现落后于大盘，但对于那些关注长期投资的人来说，它们仍然看起来具有吸引力。以下是详细情况。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://g.foolcdn.com/image//query-b3A9cmVzaXplJnVybD1odHRwczovL2cuZm9vbGNkbi5jb20vZWRpdG9yaWFsL2ltYWdlcy84Mjg1MzQvcGh5c2ljaWFuLWdpdmluZy1tZWRpY2luZS10by1lbGRlcmx5LXBhdGllbnQuanBnJnc9NzAw" alt="" original-src="https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F828534%2Fphysician-giving-medicine-to-elderly-patient.jpg&amp;op=resize&amp;w=700"/></p>
<p>Image source: Getty Images.</p>
<div class="lb-trans"><p>图片来源：Getty Images。</p>
</div><h2>1. Pfizer</h2>
<div class="lb-trans"><h2>1. 辉瑞</h2>
</div><p>Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years.</p>
<div class="lb-trans"><p>在过去几年中，辉瑞面临着财务结果恶化和某些产品竞争加剧的问题。它还面临失去其他产品专利保护的前景；这些产品包括 Eliquis，一种抗凝药，是其畅销药物之一，以及 Xtandi，一种癌症治疗药物。这两种药物将在未来几年内在美国失去专利。</p>
</div><p>These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive.</p>
<div class="lb-trans"><p>这些挑战导致了糟糕的股市表现。然而，抛售可能已经过度。在当前水平下，辉瑞的股票看起来具有吸引力。</p>
</div><p>One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030.</p>
<div class="lb-trans"><p>公司能够反弹并在长期内继续提供强劲回报的一个原因是其丰富的产品管线，特别是在肿瘤学领域，这是行业中最大的治疗领域之一。辉瑞目前拥有五种重磅癌症药物，并计划到 2030 年将这一数字提高到八种。</p>
</div><p>Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion.</p>
<div class="lb-trans"><p>辉瑞在其他领域也有令人兴奋的候选药物，近年来获得了几种新产品的批准。尽管这些产品尚未对其收入增长产生显著贡献，但随着它们获得标签扩展，最终应该会有所贡献。</p>
</div><p>The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches.</p>
<div class="lb-trans"><p>该公司的呼吸道合胞病毒（RSV）疫苗 Abrysvo 在第二季度产生了 1.43 亿美元的销售额，这对于一款在 2023 年获得批准的产品来说并不算差。它最近还在欧洲获得了针对 18 至 59 岁成人的标签扩展（之前仅适用于 60 岁及以上人群）。辉瑞应该会在 Abrysvo 和其他新产品的推出上取得进展。</p>
</div><p>The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability.</p>
<div class="lb-trans"><p>公司还在减少开支。这些举措可能部分导致辉瑞在第二季度的盈利超出预期。管理层计划在今年实现 45 亿美元的净成本节约，并在未来几年继续追求进一步的减少，这些努力应该有助于提高盈利能力。</p>
</div><p>Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors.</p>
<div class="lb-trans"><p>辉瑞是一只稳健的股息股票。其前瞻性收益率目前超过 7%，公司在过去五年中增加了 19.5% 的分红。尽管股票可能需要一些时间才能恢复，但辉瑞可能是寻求收入的投资者的优秀长期投资。</p>
</div><h2>2. Merck</h2>
<div class="lb-trans"><h2>2. 默克</h2>
</div><p>Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13.</p>
<div class="lb-trans"><p>默克面临几个问题，其中最重要的是其畅销药物癌症药物 Keytruda 的竞争加剧，以及该药物在 2028 年即将到来的专利悬崖。此外，公司的第二季度业绩也不强劲：收入同比下降 2%，至 158 亿美元，而调整后的每股收益下降 7%，至 2.13 美元。</p>
</div><p>However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon.</p>
<div class="lb-trans"><p>然而，公司也有一些亮点。最显著的是，Winrevair——其最新推出的药物之一，去年获得批准——报告销售额为 3.36 亿美元。Winrevair 是一种用于肺动脉高压的新机制治疗药物，预计很快将成为重磅药物。</p>
</div><p>Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter.</p>
<div class="lb-trans"><p>默克在动物健康领域的业务表现也很好，该领域是其领导者之一，第二季度该细分市场的销售额同比增长 11%，达到 16 亿美元。</p>
</div><p>Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines.</p>
<div class="lb-trans"><p>与此同时，默克有一些令人兴奋的产品管线候选药物，应该能帮助其克服与 Keytruda 相关的挑战。其中之一是 Keytruda 的皮下给药版本，已经通过了三期研究，将有助于延长该药物的专利保护。近年来，默克通过许可协议显著改善了其产品管线。其候选药物包括有前景的癌症产品和减肥药物。</p>
</div><p>Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation.</p>
<div class="lb-trans"><p>正如 Winrevair 似乎是一个重大成功，默克也可能开发出创新疗法，以减轻潜在的 Keytruda 相关收入损失。因此，尽管最近遭遇挫折，但考虑到默克的创新历史，该业务可能会反弹。</p>
</div><p>Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers.</p>
<div class="lb-trans"><p>谈到默克的股息计划，该公司目前提供 4.1% 的前瞻性收益率，过去五年中其股息增长了 39%。该股票仍然是股息投资者的良好选择。</p>
</div>

2 Top Dividend Stocks to Buy on the Dip

- 辛普森和默克是值得关注的股息股票，尽管面临挑战。  
- 辛普森的深厚药物管线和成本节约措施有助于其长期回报。  
- 默克的新药 Winrevair 和创新疗法可能缓解 Keytruda 的竞争压力。

两只在股价回调时值得买入的顶级股息股票